

# Modern Staging of Small Cell Lung Cancer

Gregory P. Kalemkerian, MD,<sup>a</sup> and Shirish M. Gadgeel, MD<sup>b</sup>

## Abstract

For many years, small cell lung cancer (SCLC) has been staged using the Veterans Affairs classification system, which includes only 2 stages: limited (primary tumor and regional lymph nodes within a tolerable radiation field) and extensive (anything beyond limited stage). The TNM staging system used for non-small cell lung cancer is also prognostic for SCLC and should be integrated into the classification scheme for patients with SCLC. The staging workup for SCLC has traditionally included contrast-enhanced CT scans of the chest and abdomen, bone scan, and MRI or CT scan of the brain. Recent data suggest that PET can improve both staging accuracy and treatment planning in patients with SCLC, although further prospective studies are needed to fully define its role. (*JNCCN* 2013;11:99-104)

(NCCN) is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this journal-based CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is approved for 1.0 contact hour. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation approval or endorsement of any product. Accredited status does not imply endorsement by the provider of the education activity (NCCN). Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at <http://education.nccn.org/node/8790>; and 4) view/print certificate.

Release date: January 11, 2013; Expiration date: January 11, 2014.

## NCCN: Continuing Education

### Accreditation Statement

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial support was received for this article. The National Comprehensive Cancer Network

### Learning Objectives

Upon completion of this activity, participants will be able to:

- Integrate into professional practice the TNM staging system for the classification of patients with SCLC.
- Describe the optimal staging work-up for patients with SCLC.

From the <sup>a</sup>Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, and <sup>b</sup>Department of Hematology and Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, Michigan.

Submitted August 1, 2012; accepted for publication November 12, 2012.

Dr. Kalemkerian has disclosed that he has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Gadgeel has disclosed that he is on the advisory board for MethylGene Inc.

Correspondence: Gregory P. Kalemkerian, MD, C350 Med Inn – SPC 5848, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5848. E-mail: [kalemker@umich.edu](mailto:kalemker@umich.edu)

### EDITOR

**Kerrin M. Green, MA**, Assistant Managing Editor, *Journal of the National Comprehensive Cancer Network*.

Ms. Green has disclosed that she has no relevant financial relationships.

### CE AUTHOR

**Nicole B. Fair, BS**, Manager, Continuing Education and Grants

Ms. Fair has disclosed that she has no relevant financial relationships.

**Kristina M. Gregory, RN, MSN, OCN**, Vice President, Clinical Information Operations

Ms. Gregory has disclosed that she has no relevant financial relationships.

**S**mall cell lung cancer (SCLC) is characterized by neuroendocrine differentiation, early metastatic spread, and initial responsiveness to cytotoxic therapy. Its overall incidence and proportional incidence as a percentage of all lung cancer cases have been declining over the past 2 decades, with SCLC now accounting for approximately 15% of all lung cancer cases.<sup>1</sup> Although limited-stage SCLC is potentially curable, most patients present with more advanced disease, and the overall survival of patients with SCLC remains poor. Accurate staging is a critical aspect of patient management because it not only provides important prognostic information but also determines appropriate treatment strategies.

### Staging Systems

The Veterans Administration Lung Study Group (VALSG) 2-stage classification scheme has been routinely used for the clinical staging of SCLC for at least 40 years.<sup>2</sup> The original VALSG system defined limited-stage as: 1) disease confined to 1 hemithorax, although local extension may be present; 2) no extrathoracic metastases, except for ipsilateral supraclavicular lymph nodes if they can be included in the same radiation port as the primary tumor; and 3) primary tumor and regional nodes that can be adequately encompassed in a radiation port. Extensive-stage was defined as disease that cannot be classified as limited, including malignant pleural or pericardial effusions, contralateral hilar or supraclavicular lymph nodes, and hematogenous metastases. In 1989, the International Association for the Study of Lung Cancer (IASLC) proposed a modification to the VALSG system in which limited-stage SCLC was expanded to include contralateral mediastinal or supraclavicular lymph node metastases and ipsilateral pleural effusions independent of cytology.<sup>3</sup> Extensive-stage SCLC remained any disease at sites beyond the definition of limited disease. A single-institution retrospective review of 109 patients with SCLC suggested that the IASLC staging system had better prognostic discrimination than the VALSG scheme.<sup>4</sup> In practice, most clinicians and clinical trials blend the VALSG and IASLC criteria by classifying contralateral mediastinal and ipsilateral supraclavicular lymph node involvement as limited-stage. The classification of contralateral supraclavicular or hilar lymph node involvement remains controver-

sial, with treatment usually determined individually based on the ability to include these regions in a tolerable radiotherapy port.

The use of a simplified 2-stage system is based on both the biologic characteristics of SCLC and the available therapeutic options. Most patients present with extensive-stage disease for which systemic chemotherapy is the standard treatment. All patients with limited-stage disease, regardless of the visible extent of tumor, also receive systemic chemotherapy because of the high probability of micrometastatic disease and the high initial responsiveness to cytotoxic therapy. Because all patients with SCLC will receive platinum-based chemotherapy regardless of stage, the primary stage-dependent clinical management decision is whether a local therapeutic modality (ie, radiotherapy or surgery) should be added to systemic therapy. A local modality is included in initial therapy only in patients without distant metastases (ie, patients with limited stage disease). Surgery is rarely used for treating SCLC because nearly all patients with limited-stage SCLC have bulky mediastinal lymph node involvement that is not amenable to definitive surgical resection. Therefore, the 2-stage system has worked well to define initial treatment for most patients with SCLC: chemotherapy for extensive-stage and chemoradiotherapy for limited-stage.

Recently, the IASLC proposed that the newly revised TNM staging classification for lung cancer<sup>5</sup> (staging table available online, in the NCCN Guidelines for SCLC, at NCCN.org [ST-1]) should replace the VALSG system for SCLC. This recommendation is based on a prognostic analysis of 8088 patients diagnosed with SCLC between 1990 and 2000 who were included in the IASLC database and had adequate data to determine clinical (c) or pathologic (p) TNM stage.<sup>6,7</sup> In clinically staged patients without hematogenous metastases, both the cT and cN descriptors were discriminatory for overall survival (both  $P < .0001$ ).<sup>6</sup> However, no significant survival difference was seen between the cN0 and cN1 subsets.<sup>6</sup> The overall clinical stage I–IV groupings were also predictive of overall survival, and this finding was validated in a cohort of 4884 patients with SCLC from the SEER registry.<sup>6</sup> However, cT stage seemed to be a more important prognostic predictor than cN stage, because the survival curves overlapped for patients with stages IA and IIA disease and those with IB and IIB disease.<sup>6</sup> The survival rates

## Staging of SCLC

of patients with pleural effusions but otherwise limited-stage disease were intermediate between those of patients with limited-stage disease without effusion and patients with extensive-stage disease, regardless of pleural fluid cytology. Data were insufficient to determine the prognostic impact of contralateral supraclavicular lymph node involvement compared with ipsilateral supraclavicular or contralateral mediastinal lymph node involvement.

A separate analysis of 349 patients in the IASLC database with SCLC pathologically staged by complete (R0) resection also showed the prognostic impact of the pT and pN classifiers.<sup>7</sup> Using the newer TNM system, the pathologic stage I–IV groupings also correlated with overall survival, although only the differences between stages IIB versus IIIA and IIIA versus IIIB achieved statistical significance.<sup>7</sup> An independent analysis of 10,660 patients with SCLC from the California Cancer Registry also confirmed the prognostic value of the T and N classifiers and the overall stage I–IV groupings.<sup>8</sup>

These retrospective studies support the applicability of the new TNM staging scheme to SCLC. However, the degree of prognostic discrimination with the TNM system seems less impressive for SCLC than for non–small cell lung cancer.<sup>5</sup> In addition, because most clinical trials in SCLC have used the VALSG staging system, the application of TNM staging is unlikely to significantly alter clinical decision-making. Nevertheless, TNM staging does have utility in selecting patients for surgical resection (ie, those with T1–2,N0 disease). TNM staging may also allow for improved consistency in radiation treatment planning, given the recent trend toward involved-field rather than elective nodal radiation for the treatment of limited-stage SCLC. As a rule, TNM staging should be implemented in clinical trial stratification and tumor registry accession to allow future refinement of appropriate therapeutic options.

### Staging Workup

The standard initial evaluation of patients with newly diagnosed SCLC consists of a complete medical history and physical examination, pathologic review of biopsy specimens, and laboratory studies. Because limited-stage SCLC is a potentially curable disease, the most important part of staging is screening for distant hematogenous metastases. Although SCLC can

metastasize almost anywhere in the body, the most common sites are the lungs, pleura, bones, adrenal glands, liver, and brain. Standard procedures to identify metastatic disease include contrast-enhanced CT scans of the chest and abdomen, bone scan, and MRI or CT scan of the brain. Brain imaging should be obtained in all patients with SCLC, because MRI scans will detect metastatic disease in 10% to 15% of neurologically asymptomatic patients at initial diagnosis, including 12% of patients with otherwise limited-stage SCLC.<sup>9,10</sup> Bone marrow aspiration and biopsy can detect metastatic SCLC cells in 15% to 30% of patients at diagnosis.<sup>11–13</sup> However, fewer than 5% of patients will have bone marrow involvement as the only site of metastatic disease.<sup>11–13</sup> Therefore, routine bone marrow examination is not indicated in patients with SCLC with normal blood counts. Recently, PET has been incorporated into the SCLC staging workup in conjunction with diagnostic CT scans of the chest and abdomen and brain imaging with MRI or CT.<sup>14</sup>

### PET in SCLC

The utility of PET in the initial staging of patients with SCLC was evaluated in 14 studies comparing pretreatment <sup>18</sup>F-fluorodeoxyglucose (FDG)-PET with conventional staging procedures<sup>15–28</sup> (Table 1). Each of these studies has been small (range, 7–120 patients), comprising a total of 478 patients, and only 5 studies were prospectively designed (n=209).<sup>18,20,21,23,24</sup> Study designs varied regarding the specific conventional staging procedures, the use of PET alone or PET/CT, and the methods used to define PET positivity. In addition, some studies required biopsy of all FDG-avid lesions that would alter stage, whereas others used clinical or further imaging follow-up to confirm PET findings. Unfortunately, several studies did not validate PET findings using any other method.

Because of the high metabolic activity of SCLC, the sensitivity of PET for the detection of primary tumors is 100%.<sup>15–17,20,21,23,28</sup> Overall, cumulative staging concordance between PET and conventional imaging was 84%,<sup>15–28</sup> with better concordance in the prospective (89%; range, 83%–100%) than the retrospective (81%; range, 50%–100%) studies. Of the 274 patients with limited-stage SCLC according to conventional imaging, 18% were upstaged to extensive stage based on PET results, with similar findings in the prospective (17%; range, 0%–33%) and

Kalemkerian and Gadgeel

**Table 1** PET for Initial Staging of Small Cell Lung Cancer

| Trial                           | N          | Stage Concordance | LS         |                  | ES         |                    |
|---------------------------------|------------|-------------------|------------|------------------|------------|--------------------|
|                                 |            |                   | n          | Upstaged (LS→ES) | n          | Downstaged (ES→LS) |
| <i>Prospective</i>              |            |                   |            |                  |            |                    |
| Chin et al. <sup>18</sup>       | 18         | 83%               | 9          | 22%              | 9          | 11%                |
| Bradley et al. <sup>20</sup>    | 24         | 88%               | 24         | 8%               | –          | –                  |
| Brink et al. <sup>21</sup>      | 120        | 88%               | 51         | 20%              | 69         | 4%                 |
| Kut et al. <sup>23</sup>        | 18         | 100%              | 6          | 0                | 12         | 0                  |
| Fischer et al. <sup>24</sup>    | 29         | 83%               | 9          | 33%              | 20         | 5%                 |
| <b>Subtotal</b>                 | <b>209</b> | <b>89%</b>        | <b>99</b>  | <b>17%</b>       | <b>110</b> | <b>5%</b>          |
| <i>Retrospective</i>            |            |                   |            |                  |            |                    |
| Hauber et al. <sup>15</sup>     | 7          | 100%              | 6          | 0                | 1          | 0                  |
| Schumacher et al. <sup>16</sup> | 26         | 73%               | 13         | 54%              | 13         | 0                  |
| Shen et al. <sup>17</sup>       | 25         | 92%               | 10         | 10%              | 15         | 7%                 |
| Kamel et al. <sup>19</sup>      | 24         | 83%               | 17         | 18%              | 7          | 14%                |
| Blum et al. <sup>22</sup>       | 15         | 67%               | 15         | 33%              | –          | –                  |
| Niho et al. <sup>25</sup>       | 63         | 92%               | 63         | 8%               | –          | –                  |
| Vinjamuri et al. <sup>26</sup>  | 51         | 82%               | 18         | 6%               | 33         | 18%                |
| Azad et al. <sup>27</sup>       | 46         | 74%               | 26         | 15%              | 20         | 40%                |
| Arslan et al. <sup>28</sup>     | 12         | 50%               | 7          | 71%              | 5          | 20%                |
| <b>Subtotal</b>                 | <b>269</b> | <b>81%</b>        | <b>175</b> | <b>18%</b>       | <b>94</b>  | <b>18%</b>         |
| <b>Total</b>                    | <b>478</b> | <b>84%</b>        | <b>274</b> | <b>18%</b>       | <b>204</b> | <b>11%</b>         |

Abbreviations: ES, extensive stage; LS, limited stage.

retrospective (18%; range, 0%–71%) studies.<sup>15–28</sup> Of the 204 patients with extensive-stage SCLC on conventional imaging, 11% were downstaged to limited stage based on PET results, with a much lower percentage of downstaged patients noted in the prospective (5%; range, 0%–11%) than retrospective (18%; range, 0%–40%) studies.<sup>15–19,21,23,24,26–28</sup> PET was superior to standard imaging in both sensitivity and specificity at most metastatic sites of disease.<sup>15–17,20,21</sup> However, PET was inferior to MRI or CT for the detection of brain metastases.<sup>21,26</sup>

Seven studies have evaluated changes in initial management based on PET in patients with SCLC (Table 2).<sup>19,20,22,23,27,29,30</sup> Overall, PET findings led to a change in initial management in 28% (range, 0%–47%) of 211 patients. Of the 59 patients with a change in management, 32% underwent an alteration in the general treatment plan as a result of stage shift, whereas 68% had changes in the extent of the radiation field for the treatment of limited-stage SCLC. In one of these studies, only 3% of patients who underwent PET-

guided radiation planning had isolated nodal failure, compared with 11% of historical controls who underwent CT-guided radiation planning, suggesting that the incorporation of PET into radiation planning improved regional disease control.<sup>30</sup>

Only 4 studies, all retrospective, have assessed the use of PET in restaging of SCLC after initial therapy.<sup>16,19,22,28</sup> Major differences in the analytic methods of these studies makes it difficult to generalize findings, but overall 20% to 57% of patients were found to have more disease and 14% to 38% less disease based on PET results compared with traditional CT restaging alone.<sup>16,19,22,28</sup>

Overall, the use of PET, in addition to CT scans of the chest and abdomen and MRI or CT of the brain, seems to improve the accuracy of initial staging and radiotherapy planning in patients with SCLC. If PET is obtained for initial staging, pathologic confirmation is required for findings that result in staging changes that would affect clinical management. However, further well-designed prospective trials with pathologic confirmation of imaging

Staging of SCLC

**Table 2 Change in Initial Management Based on PET Findings**

| Trial                         | N          | Change in Management | Change in RT Field (n=190) | Change in Treatment (n=130) |
|-------------------------------|------------|----------------------|----------------------------|-----------------------------|
| <i>Prospective</i>            |            |                      |                            |                             |
| Bradley et al. <sup>20</sup>  | 24         | 33%                  | 29%                        | 4%                          |
| Kut et al. <sup>23</sup>      | 21         | 0                    | NR                         | 0                           |
| von Loon et al. <sup>30</sup> | 60         | 30%                  | 30%                        | NR                          |
| <i>Retrospective</i>          |            |                      |                            |                             |
| Kamel et al. <sup>19</sup>    | 24         | 37%                  | 21%                        | 17%                         |
| Blum et al. <sup>22</sup>     | 15         | 47%                  | 13%                        | 33%                         |
| Azad et al. <sup>27</sup>     | 46         | 26%                  | 7%                         | 20%                         |
| von Loon et al. <sup>29</sup> | 21         | 24%                  | 24%                        | NR                          |
| <b>Total</b>                  | <b>211</b> | <b>28%</b>           | <b>21%</b>                 | <b>15%</b>                  |

Abbreviations: NR, not reported; RT, radiotherapy.

findings are still needed to fully determine if the addition of PET to conventional staging procedures has a favorable impact on overall clinical outcome in patients with SCLC.

### Conclusions

Although SCLC remains an overwhelmingly devastating disease, advances in staging technology have allowed practitioners to better focus aggressive treatments on patients who will most benefit. The emergence of PET may allow further discrimination between potentially curable patients with limited-stage SCLC and those with extensive-stage SCLC for whom palliative treatment remains the only option. Although the 2-stage VALSG staging criteria have provided adequate classification for many years, the time has come to integrate the TNM system into the evaluation of patients with SCLC. As therapy improves over time, the finer parsing of disease extent provided by TNM staging will hopefully allow practitioners to better define more specific and appropriate individualized treatments for patients with SCLC.

### References

1. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results database [abstract]. *J Clin Oncol* 2006;24(18S-Part I):Abstract 384s.
2. Zelen M. Keynote address on biostatistics and data retrieval. *Cancer Chemother Rep (Part 3)* 1973;4:31–42.
3. Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic

factors in small cell lung cancer: a consensus report. *Lung Cancer* 1989;5:119–126.

4. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? *Lung Cancer* 2002;37:271–276.
5. American Joint Committee on Cancer. *AJCC Cancer Staging Handbook*, 7th Edition. Springer, NY: New York; 2010:299–323.
6. Shepherd FA, Crowley J, Van Houtte P, et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol* 2007;2:1067–1077.
7. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009;4:1049–1059.
8. Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer with comparison to the current UICC 6th TNM edition. *J Thorac Oncol* 2009;4:300–310.
9. Hochstenbag MMH, Twijningstra A, Wilmink JT, et al. Asymptomatic brain metastases in small cell lung cancer: MR-imaging is useful at initial diagnosis. *J Neurooncol* 2000;48:243–248.
10. Seute T, Leffers P, Wilmink, JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. *J Clin Oncol* 2006;24:2079–2083.
11. Campling B, Quirt I, DeBoer G, et al. Is bone marrow examination in small-cell lung cancer really necessary? *Ann Int Med* 1986;105:508–512.
12. Tritz DB, Doll DC, Ringenberg QS, et al. Bone marrow involvement in small cell lung cancer: clinical significance and correlation with routine laboratory variables. *Cancer* 1989;63:763–766.
13. Levitan N, Byrne RE, Bromer RH, et al. The value of the bone scan and bone marrow biopsy in staging small cell lung cancer. *Cancer* 1985;56:652–654.
14. Kalemkerian GP, Akerley W, Bogner P, et al. *NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer*. Version 2, 2012. Available at: [NCCN.org](http://NCCN.org). Accessed November 20, 2012.
15. Hauber HP, Bohuslavizki KH, Lund CH, et al. Positron emission

Kalemkerian and Gadgeel

- tomography in the staging of small-cell lung cancer: a preliminary study. *Chest* 2001;119:950–954.
16. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. *Eur J Nucl Med* 2001;28:483–488.
  17. Shen YY, Shiau YC, Wang JJ, et al. Whole-body  $^{18}\text{F}$ -2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. *Anticancer Res* 2002;22:1257–1264.
  18. Chin R, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. *Lung Cancer* 2002;37:1–6.
  19. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body  $^{18}\text{F}$ -FDG PET improves the management of patients with small cell lung cancer. *J Nucl Med* 2003;44:1911–1917.
  20. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. *J Clin Oncol* 2004;22:3248–3254.
  21. Brink I, Schumacher T, Mix M, et al. Impact of [ $^{18}\text{F}$ ]FDG-PET on the primary staging of small-cell lung cancer. *Eur J Nucl Med Mol Imaging* 2004;31:1614–1620.
  22. Blum R, MacManus MP, Rischin D, et al. Impact of positron emission tomography on the management of patients with small cell lung cancer: preliminary experience. *Am J Clin Oncol* 2004;27:164–171.
  23. Kut V, Spies W, Spies S, et al. Staging and monitoring of small cell lung cancer using [ $^{18}\text{F}$ ]fluoro-2-deoxy-D-glucose-positron emission tomography. *Am J Clin Oncol* 2007;30:45–50.
  24. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. *Ann Oncol* 2007;18:338–345.
  25. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET scan in apparent limited-disease small-cell lung cancer. *Lung Cancer* 2007;57:328–333.
  26. Vinjamuri M, Craig M, Campbell-Fontaine A, et al. Can positron emission tomography be used as a staging tool for small-cell lung cancer? *Clin Lung Cancer* 2008;9:30–34.
  27. Azad A, Chionh F, Scott AM, et al. High impact of  $^{18}\text{F}$ -FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. *Mol Imaging Biol* 2010;12:443–451.
  28. Arslan N, Tuncel M, Kuzhan O, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[ $^{18}\text{F}$ ] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. *Ann Nucl Med* 2011;25:406–413.
  29. van Loon J, Offerman C, Bosmans G, et al.  $^{18}\text{F}$ FDG-PET based radiation planning of the mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. *Radiother Oncol* 2008;87:49–54.
  30. van Loon J, De Ruyscher D, Wanders R, et al. Selective nodal irradiation on basis of  $^{18}\text{F}$ FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. *Int J Radiat Oncol Biol Phys* 2010;77:329–336.

## Instructions for Completion

To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at <http://education.nccn.org/node/8790>; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-

choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet

## Posttest Questions

1. Small cell lung cancer (SCLC) is characterized by:
  - a. Neuroendocrine differentiation
  - b. Early metastatic spread
  - c. Initial responsiveness to cytotoxic therapy
  - d. All of the above
2. True or False: Most patients with SCLC present with extensive-stage disease, for which surgery is the standard treatment.

3. Standard procedures to identify metastatic disease include:
  - a. Contrast-enhanced CT scans of the chest and abdomen
  - b. Bone scan
  - c. MRI or CT scan of the brain
  - d. All of the above

